PRESS STATEMENT: National Health Expenditure Projections Show Sharp Rise in Rx Spending

07-29-2015 Blog PostsPress Release

“These numbers paint a troubling picture for the future of the American economy. The dramatic rise in prescription drug spending proves that it is more important than ever to advance a solution to monopolistic drug pricing. We cannot afford to continue on this unsustainable path.”

PRESS STATEMENT: FDA Approves Praluent, New Cholesterol-Lowering Treatment

07-24-2015 Blog PostsPress Release

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but it’s price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years.”

PRESS STATEMENT: New Report Shows Medicare Spending Increase Driven By Specialty Drug Prices

07-22-2015 Blog PostsPress Release

PRESS STATEMENT: New Report Shows Medicare Spending Increase Driven By Specialty Drug Prices

PRESS STATEMENT: New Report Shows Hepatitis C Drugs Have Costly Impact on California

07-1-2015 Blog PostsPress Release

Exorbitant price tags for specialty medications are taking a serious financial toll on state budgets. A new analysis released yesterday from the California Association of Health Plans (CAHP) shows that treating only 10 percent of 175,000 patients in state-funded health care programs with just three hepatitis C medications would cost California roughly $1-2 billion.

PRESS STATEMENT: New Kaiser Family Foundation Poll Reinforces Need for Sustainable Drug Pricing

06-16-2015 Blog PostsPress Release

John Rother, President of the National Coalition on Health Care and Chair of the Campaign for Sustainable Rx Pricing issued the following statement in response to a recent health tracking poll by the Kaiser Family Foundation that found that an overwhelming 76% of Americans blame pharmaceutical companies for the rising cost of medicines.

ICYMI: New poll shows 75% of Americans find Rx prices are just too high.

05-21-2015 Blog PostsPress Release

May 21, 2015 Morning Consult: “New Cures, Old Problems: Poll Shows Drug Affordability Addles Americans” “The House Energy and Commerce Committee is slated to vote today on legislation that offers incentives to the pharmaceutical industry to develop new drugs and devices. But the bill does little immediately to address what a new Morning Consult poll found […]

ICYMI: “Prescription drug prices climb into the stratosphere”

05-20-2015 Blog PostsPress Release

May 20, 2015 “Prescription drug prices climb into the stratosphere” by Trudy Lieberman, Rural Health News Service Note: Article originally printed in Sterling Journal-Advocate.  There’s no getting around it. Americans are using more medications and spending more for them. The latest evidence just came from Express Scripts, the pharmacy benefit manager, which acts as a middleman […]

ICYMI: New study answers the age old question, “Does R&D really justify high drug costs?” (Spoiler alert: the answer is no.)

05-15-2015 Blog PostsPress Release

ICYMI – May 15, 2015 ***** The New England Journal of Medicine: “The $2.6 Billion Pill — Methodologic and Policy Considerations” “Of course, it is extremely expensive and risky to develop a new medication…but as risky as drug development is, the pharmaceutical and biotech industries remain among the most profitable sectors of the U.S. economy and actually […]

ICYMI: In anticipation of today’s Cures markup, E&C releases an updated draft while Pew launches a new Rx initiative

05-14-2015 Blog PostsPress Release

May 14, 2015 The House Energy and Commerce Committee released an updated draft of the 21st Century Cures bill last night in a last minute effort to address concerns over drug exclusivity, interoperability and tele health before today’s markup. However, many organizations are still concerned about Congress’ lack of legislation to address high drug costs. Pew Charitable Trusts […]

ICYMI: FDA Advisory Panel Approves New Cystic-Fibrosis Drug while Americans Continue to Pay the Price of High Cost Drugs

05-13-2015 Blog PostsPress Release

May 13, 2015 The New York Times: “Cystic Fibrosis Drug Wins Approval of F.D.A. Advisory Panel” “If the drug is approved, Vertex could still face challenges getting insurers to pay for it, given the somewhat questionable efficacy. Kalydeco costs more than $300,000 a year, although Orkambi is expected to be a little less expensive, because it […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.